Search Results
Results found for "GPCR Research"
- Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Serotonin Receptor 5-HT2A Regulates TrkB Receptor Function in Heteroreceptor Complexes
Read more at the source #DrGPCR #GPCR #IndustryNews
- Sosei Heptares recently hosted their annual Scientific Advisory Board (SAB)
Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex Raises $10 Million In Equity Financing
Read more at the source #DrGPCR #GPCR #IndustryNews
- Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine...
" Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
Read more at the source #DrGPCR #GPCR #IndustryNews
- Platelets in the NETworks interweaving inflammation and thrombosis
Research over the past years has provided a substantial body of evidence demonstrating that platelets Read more at the source #DrGPCR #GPCR #IndustryNews
- Domain Therapeutics Raises $42m Series A Financing
STRASBOURG, France & MONTREAL- Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology Read more at the source #DrGPCR #GPCR #IndustryNews
- Signaling pathways activated by sea bass gonadotropin-inhibitory hormone peptides in COS-7 cells...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Induced Human Regulatory T Cells Express the Glucagon-like Peptide-1 Receptor
Read more at the source #DrGPCR #GPCR #IndustryNews
- Regulation of rod photoreceptor function by farnesylated G-protein γ-subunits
Read more at the source #DrGPCR #GPCR #IndustryNews
- Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Targeting the M1 muscarinic receptor in neurodegenerative disease
Translational Sciences Associate Director at Sosei Heptares, recently presented at the Keystone Symposia GPCR Read more at the source #DrGPCR #GPCR #IndustryNews
- β2-Adrenergic Receptor Expression and Intracellular Signaling in B Cells Are Highly Dynamic during..
Read more at the source #DrGPCR #GPCR #IndustryNews
- Michel Bouvier appointed Knight of the Ordre national du Québec
Michel Bouvier, Chief Executive Officer of IRIC, Principal Investigator of the Molecular Pharmacology Research Read more at the source #DrGPCR #GPCR #IndustryNews
- Effects of Small Molecule Ligands on ACKR3 Receptors
Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex raises $4.2 million in equity financing
issuance and will expire five years from their date of issuance. " Read more at the source #DrGPCR #GPCR
- Third Rock pushes newest fund over $1B line as it marks 15 years in venture capital
Read more at the source #DrGPCR #GPCR #IndustryNews
- Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology
March 2022 "Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in immunoresistance company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs The two companies will combine their expertise to identify GPCR targets and associated biomarkers to Read more at the source #DrGPCR #GPCR #IndustryNews
- When January Looks Different by March: Orthosteric vs. Allosteric Insights from Our Latest AMA
recent live Ask Me Anything (AMA) session, where members brought forward active questions from their GPCR submit questions in advance to: terry@drgpcr.org Distinguishing Orthosteric vs Allosteric Mechanisms in GPCR for interpreting Schild plot deviations and probe dependence Operational practices that strengthen GPCR GPCR systems are sensitive and context-dependent. Forty years of pharmacological expertise — organized into a year-round learning framework for serious GPCR
- Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of ...
These molecules are then evaluated at unprecedented speed and scale on hundreds of GPCR targets simultaneously Read more at the source #DrGPCR #GPCR #IndustryNews
- Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls
GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry ll gain: Why saturation and displacement assays fail when protein stoichiometry shifts How two-stage GPCR Complex Two-Stage Biology Behind Orthosteric Binding GPCR pharmacology rarely follows the neat Langmuir Clues that point to true multiple-site binding rather than two-stage GPCR biology: Disrupting G protein leaders who need credible guidance fast, the Corner brings clarity to the complexities shaping modern GPCR
- ShouTi Pharma CEO Dr. Raymond Stevens was interviewed by Moira Gunn of the NPR TechNation podcast
April 2022 Read more at the source #DrGPCR #GPCR #IndustryNews
- Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...
Changes to Drive the Company Through the Next Stage of its Evolution "New team focused on expanding its GPCR-focused Read more at the source #DrGPCR #GPCR #IndustryNews
- Dr. Kevin Pfleger and Dr. Elizabeth Johnstone were awarded one of the 2022 Diabetes Research...
Elizabeth Johnstone were awarded one of the 2022 Diabetes Research Grants at the World Diabetes Day Breakfast Perkins Professor Kevin Pfleger and Dr Elizabeth Johnstone who were awarded one of the 2022 Diabetes Research This $60,000 grant from Diabetes Research WA will assist the Perkins' Molecular Endocrinology and Pharmacology Read more at the source #DrGPCR #GPCR #IndustryNews
- John Streicher talks about his work on terpenes found in cannabis as these may be a novel way to ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
Read more at the source #DrGPCR #GPCR #IndustryNews
- Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment ...
– Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs pharmacokinetics of CFTX-1554 in healthy subjects (NCT05260658). " Read more at the source #DrGPCR #GPCR
- Modulation of Striatal Adenosinergic Function by HTL0041178, a Selective GPR52 Agonist
control neuropsychiatric symptoms in conditions such as schizophrenia. " Read more at the source #DrGPCR #GPCR
- Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare ...
Read more at the source #DrGPCR #GPCR #IndustryNews
